| Project ID | IMP_100020 |
| Title | Understanding the impact of Immunosenescence in bacterial endophthalmitis |
| Uploaded by | Joveeta |
| Research Area | Biological Sciences |
| Funding Source | Hyderabad Eye Research Foundation |
| Contributors | Sreyasi Maiti, Joveeta Joseph |
| Description | Endophthalmitis is a sight threatening infection occurring when pathogens gain access to the inner coats of the eye. Delayed presentation of the patients to the hospital and rapid progression of the infection often leads to poor disease prognosis and vision loss despite prompt treatment administration. Regardless of the massive advancement in the infrastructure and strict adherence to the healthcare sterilization protocols, incidence of endophthalmitis in India remains up to 1.2%. With aging population on a steady rise, number of cataract surgeries and therapeutic interventions for glaucoma, age-related macular degeneration and other retinal ailments, have also increased and so is the risk of endophthalmitis. Endophthalmitis in aged individuals (>60 years) is therapeutically challenging and one of the major reason is the poor understanding of the immunology of aging. The burden of the senescent cells in the aged individuals will bring about a multifactorial changes leading to immunosenescence, inflammaging and immunometabolism. Multiomics has gained a lot of popularity in the recent decades and metabolomics studies have analysed the interplay of small molecules in driving the aging process and also its associated biological processes including immunometabolism. Metabolic control of the immune system provides insight into the cellular mechanisms influencing immune cells fate and functions. Additionally, metabolic pathways such as fatty acid oxidation, glycolysis, amino acid metabolism, tricarboxylic acid and fatty acid synthesis regulate cell extrinsic and intrinsic signals modulating immune cell metabolism especially T cell metabolism. T cell function requires complex orchestration of metabolic switching and it is hypothesized that T cells also undergo senescence since they lose the ability to secrete cytokines. Comparative analysis of metabolic regulations of senescence and inflammation in young and aged individuals during endophthalmitis could pave way for deeper insights into the pathobiology and progression of infection. This study answers some of the major unanswered questions. (1) Does senescence of retinal cells affect the infection resolution in aged individuals? (2) How does metabolites regulate senescence and inflammation in endophthalmitis? (3) Does clearance of senescent cells with senolytics improve treatment outcome and vision recovery? The outcome of this study might possibly alter the current treatment administered to aged individuals. With the possibility of strong translational value, we aim to take the identified and in vivo assessed senolytics and senomorphics to clinical trials. |
| Study ID | IMS_100016 |
| Title | Understanding the impact of immunosenescence in bacterial endophthalmitis |
| Uploaded by | Joveeta |
| Study Type | Mass Spectrometry (MS) |
| Data Type | Untargeted |
| Release Date | Dec. 18, 2024 |
| IEC/IBSC No. | LEC-BHR-P-05-23-1045 |
| Publication | http://doi.org/10.1167/iovs.65.13.6 |
| Summary | In our study, we observed the elevated presence of metabolites such as hippuric acid, taurine, phenylalanine, and N-acetyl-l-aspartic acid in aged individuals with endophthalmitis. Understanding these metabolic shifts can provide insights into the pathophysiology of age-related diseases while also opening up additional avenues for developing new diagnostic and therapeutic approaches. Dysregulation in metabolites belonging to the purine, carnitine, TCA cycle, polyamine, and amino acid (arginine, histidine, and taurine) metabolic pathways was commonly altered in older patients with endophthalmitis. Targeting these metabolic pathways and addressing the weakened metabolic responses or chronic inflammation associated with aging could lead to the development of innovative therapeutic strategies, such as anti-apoptotic or senolytic agents, ultimately providing potential therapeutic insights and enhancing clinical outcomes. |
| # | Sample ID | Sample Name | Organism | Source | Sample Type | Experimental Condition | Gender | Age | Replicates | Storage | Files/Sample |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | IMSM_100855 | Y3 | Pseudomonas aeruginosa | Human Vitreous | Human Vitreous | Diseased | M | 13 | 3 | minus 20° | |
| 2 | IMSM_100856 | Y4 | Pseudomonas aeruginosa | Human Vitreous | Human Vitreous | Diseased | M | 25 | 3 | minus 20° | |
| 3 | IMSM_100857 | Y5 | Pseudomonas aeruginosa | Human Vitreous | Human Vitreous | Diseased | M | 12 | 3 | minus 20° | |
| 4 | IMSM_100858 | Y6 | Pseudomonas aeruginosa | Human Vitreous | Human Vitreous | Diseased | M | 18 | 3 | minus 20° | |
| 5 | IMSM_100859 | CY2 | Pseudomonas aeruginosa | Human Vitreous | Human Vitreous | non-infectious | M | 22 | 3 | minus 20° | |
| 6 | IMSM_100860 | CY3 | Pseudomonas aeruginosa | Human Vitreous | Human Vitreous | non-infectious | F | 26 | 3 | minus 20° | |
| 7 | IMSM_100861 | CY4 | Pseudomonas aeruginosa | Human Vitreous | Human Vitreous | non-infectious | M | 26 | 3 | minus 20° | |
| 8 | IMSM_100862 | CY5 | Pseudomonas aeruginosa | Human Vitreous | Human Vitreous | non-infectious | M | 28 | 3 | minus 20° | |
| 9 | IMSM_100863 | M2 | Pseudomonas aeruginosa | Human Vitreous | Human Vitreous | Diseased | M | 51 | 3 | minus 20° | |
| 10 | IMSM_100864 | M3 | Pseudomonas aeruginosa | Human Vitreous | Human Vitreous | Diseased | M | 40 | 3 | minus 20° | |
| 11 | IMSM_100865 | M4 | Pseudomonas aeruginosa | Human Vitreous | Human Vitreous | Diseased | M | 48 | 3 | minus 20° | |
| 12 | IMSM_100866 | M5 | Pseudomonas aeruginosa | Human Vitreous | Human Vitreous | Diseased | M | 50 | 3 | minus 20° | |
| 13 | IMSM_100867 | M6 | Pseudomonas aeruginosa | Human Vitreous | Human Vitreous | Diseased | M | 49 | 3 | minus 20° | |
| 14 | IMSM_100868 | CM2 | Pseudomonas aeruginosa | Human Vitreous | Human Vitreous | non-infectious | M | 39 | 3 | minus 20° | |
| 15 | IMSM_100869 | CM3 | Pseudomonas aeruginosa | Human Vitreous | Human Vitreous | non-infectious | M | 55 | 3 | minus 20° | |
| 16 | IMSM_100870 | CM4 | Pseudomonas aeruginosa | Human Vitreous | Human Vitreous | non-infectious | M | 56 | 3 | minus 20° | |
| 17 | IMSM_100871 | CM5 | Pseudomonas aeruginosa | Human Vitreous | Human Vitreous | non-infectious | M | 45 | 3 | minus 20° | |
| 18 | IMSM_100872 | O1 | Pseudomonas aeruginosa | Human Vitreous | Human Vitreous | Diseased | M | 61 | 3 | minus 20° | |
| 19 | IMSM_100873 | O2 | Pseudomonas aeruginosa | Human Vitreous | Human Vitreous | Diseased | F | 72 | 3 | minus 20° | |
| 20 | IMSM_100874 | O3 | Pseudomonas aeruginosa | Human Vitreous | Human Vitreous | Diseased | M | 66 | 3 | minus 20° | |
| 21 | IMSM_100875 | O5 | Pseudomonas aeruginosa | Human Vitreous | Human Vitreous | Diseased | M | 67 | 3 | minus 20° | |
| 22 | IMSM_100876 | O6 | Pseudomonas aeruginosa | Human Vitreous | Human Vitreous | Diseased | F | 61 | 3 | minus 20° | |
| 23 | IMSM_100877 | O8 | Pseudomonas aeruginosa | Human Vitreous | Human Vitreous | Diseased | F | 66 | 3 | minus 20° | |
| 24 | IMSM_100878 | CO1 | Pseudomonas aeruginosa | Human Vitreous | Human Vitreous | non-infectious | F | 70 | 3 | minus 20° | |
| 25 | IMSM_100879 | CO2 | Pseudomonas aeruginosa | Human Vitreous | Human Vitreous | non-infectious | F | 62 | 3 | minus 20° | |
| 26 | IMSM_100880 | CO3 | Pseudomonas aeruginosa | Human Vitreous | Human Vitreous | non-infectious | F | 62 | 3 | minus 20° | |
| 27 | IMSM_100881 | CO4 | Pseudomonas aeruginosa | Human Vitreous | Human Vitreous | non-infectious | M | 65 | 3 | minus 20° | |
| 28 | IMSM_100882 | CO5 | Pseudomonas aeruginosa | Human Vitreous | Human Vitreous | non-infectious | F | 69 | 3 | minus 20° |
| # | MS Exp ID | Sample Name / ID | MS Type | Instrument Name | Instrument Type | Ionization Method | Ion Mode | Software Used |
|---|---|---|---|---|---|---|---|---|
| 1 | IME_100506 | Y3 / IMSM_100855 | TripleTOF 5600+ System | ABI Sciex 5500 QTrap | high-resolution MS and tandem mass spectrometry (MS/MS) | Duo Spray Ion Source | Positive and Negative ran separately | SCIEX MarkerView Software |
| 2 | IME_100507 | Y4 / IMSM_100856 | TripleTOF 5600+ System | ABI Sciex 5500 QTrap | high-resolution MS and tandem mass spectrometry (MS/MS) | Duo Spray Ion Source | Positive and Negative ran separately | SCIEX MarkerView Software |
| 3 | IME_100508 | Y5 / IMSM_100857 | TripleTOF 5600+ System | ABI Sciex 5500 QTrap | high-resolution MS and tandem mass spectrometry (MS/MS) | Duo Spray Ion Source | Positive and Negative ran separately | SCIEX MarkerView Software |
| 4 | IME_100509 | Y6 / IMSM_100858 | TripleTOF 5600+ System | ABI Sciex 5500 QTrap | high-resolution MS and tandem mass spectrometry (MS/MS) | Duo Spray Ion Source | Positive and Negative ran separately | SCIEX MarkerView Software |
| 5 | IME_100510 | CY2 / IMSM_100859 | TripleTOF 5600+ System | ABI Sciex 5500 QTrap | high-resolution MS and tandem mass spectrometry (MS/MS) | Duo Spray Ion Source | Positive and Negative ran separately | SCIEX MarkerView Software |
| 6 | IME_100511 | CY3 / IMSM_100860 | TripleTOF 5600+ System | ABI Sciex 5500 QTrap | high-resolution MS and tandem mass spectrometry (MS/MS) | Duo Spray Ion Source | Positive and Negative ran separately | SCIEX MarkerView Software |
| 7 | IME_100512 | CY4 / IMSM_100861 | TripleTOF 5600+ System | ABI Sciex 5500 QTrap | high-resolution MS and tandem mass spectrometry (MS/MS) | Duo Spray Ion Source | Positive and Negative ran separately | SCIEX MarkerView Software |
| 8 | IME_100513 | CY5 / IMSM_100862 | TripleTOF 5600+ System | ABI Sciex 5500 QTrap | high-resolution MS and tandem mass spectrometry (MS/MS) | Duo Spray Ion Source | Positive and Negative ran separately | SCIEX MarkerView Software |
| 9 | IME_100514 | M2 / IMSM_100863 | TripleTOF 5600+ System | ABI Sciex 5500 QTrap | high-resolution MS and tandem mass spectrometry (MS/MS) | Duo Spray Ion Source | Positive and Negative ran separately | SCIEX MarkerView Software |
| 10 | IME_100515 | M3 / IMSM_100864 | TripleTOF 5600+ System | ABI Sciex 5500 QTrap | high-resolution MS and tandem mass spectrometry (MS/MS) | Duo Spray Ion Source | Positive and Negative ran separately | SCIEX MarkerView Software |
| 11 | IME_100516 | M4 / IMSM_100865 | TripleTOF 5600+ System | ABI Sciex 5500 QTrap | high-resolution MS and tandem mass spectrometry (MS/MS) | Duo Spray Ion Source | Positive and Negative ran separately | SCIEX MarkerView Software |
| 12 | IME_100517 | M5 / IMSM_100866 | TripleTOF 5600+ System | ABI Sciex 5500 QTrap | high-resolution MS and tandem mass spectrometry (MS/MS) | Duo Spray Ion Source | Positive and Negative ran separately | SCIEX MarkerView Software |
| 13 | IME_100518 | M6 / IMSM_100867 | TripleTOF 5600+ System | ABI Sciex 5500 QTrap | high-resolution MS and tandem mass spectrometry (MS/MS) | Duo Spray Ion Source | Positive and Negative ran separately | SCIEX MarkerView Software |
| 14 | IME_100519 | CM2 / IMSM_100868 | TripleTOF 5600+ System | ABI Sciex 5500 QTrap | high-resolution MS and tandem mass spectrometry (MS/MS) | Duo Spray Ion Source | Positive and Negative ran separately | SCIEX MarkerView Software |
| 15 | IME_100520 | CM3 / IMSM_100869 | TripleTOF 5600+ System | ABI Sciex 5500 QTrap | high-resolution MS and tandem mass spectrometry (MS/MS) | Duo Spray Ion Source | Positive and Negative ran separately | SCIEX MarkerView Software |
| 16 | IME_100521 | CM4 / IMSM_100870 | TripleTOF 5600+ System | ABI Sciex 5500 QTrap | high-resolution MS and tandem mass spectrometry (MS/MS) | Duo Spray Ion Source | Positive and Negative ran separately | SCIEX MarkerView Software |
| 17 | IME_100522 | CM5 / IMSM_100871 | TripleTOF 5600+ System | ABI Sciex 5500 QTrap | high-resolution MS and tandem mass spectrometry (MS/MS) | Duo Spray Ion Source | Positive and Negative ran separately | SCIEX MarkerView Software |
| 18 | IME_100523 | O1 / IMSM_100872 | TripleTOF 5600+ System | ABI Sciex 5500 QTrap | high-resolution MS and tandem mass spectrometry (MS/MS) | Duo Spray Ion Source | Positive and Negative ran separately | SCIEX MarkerView Software |
| 19 | IME_100524 | O2 / IMSM_100873 | TripleTOF 5600+ System | ABI Sciex 5500 QTrap | high-resolution MS and tandem mass spectrometry (MS/MS) | Duo Spray Ion Source | Positive and Negative ran separately | SCIEX MarkerView Software |
| 20 | IME_100525 | O3 / IMSM_100874 | TripleTOF 5600+ System | ABI Sciex 5500 QTrap | high-resolution MS and tandem mass spectrometry (MS/MS) | Duo Spray Ion Source | Positive and Negative ran separately | SCIEX MarkerView Software |
| 21 | IME_100526 | O5 / IMSM_100875 | TripleTOF 5600+ System | ABI Sciex 5500 QTrap | high-resolution MS and tandem mass spectrometry (MS/MS) | Duo Spray Ion Source | Positive and Negative ran separately | SCIEX MarkerView Software |
| 22 | IME_100527 | O6 / IMSM_100876 | TripleTOF 5600+ System | ABI Sciex 5500 QTrap | high-resolution MS and tandem mass spectrometry (MS/MS) | Duo Spray Ion Source | Positive and Negative ran separately | SCIEX MarkerView Software |
| 23 | IME_100528 | O8 / IMSM_100877 | TripleTOF 5600+ System | ABI Sciex 5500 QTrap | high-resolution MS and tandem mass spectrometry (MS/MS) | Duo Spray Ion Source | Positive and Negative ran separately | SCIEX MarkerView Software |
| 24 | IME_100529 | CO1 / IMSM_100878 | TripleTOF 5600+ System | ABI Sciex 5500 QTrap | high-resolution MS and tandem mass spectrometry (MS/MS) | Duo Spray Ion Source | Positive and Negative ran separately | SCIEX MarkerView Software |
| 25 | IME_100530 | CO2 / IMSM_100879 | TripleTOF 5600+ System | ABI Sciex 5500 QTrap | high-resolution MS and tandem mass spectrometry (MS/MS) | Duo Spray Ion Source | Positive and Negative ran separately | SCIEX MarkerView Software |
| 26 | IME_100531 | CO3 / IMSM_100880 | TripleTOF 5600+ System | ABI Sciex 5500 QTrap | high-resolution MS and tandem mass spectrometry (MS/MS) | Duo Spray Ion Source | Positive and Negative ran separately | SCIEX MarkerView Software |
| 27 | IME_100532 | CO4 / IMSM_100881 | TripleTOF 5600+ System | ABI Sciex 5500 QTrap | high-resolution MS and tandem mass spectrometry (MS/MS) | Duo Spray Ion Source | Positive and Negative ran separately | SCIEX MarkerView Software |
| 28 | IME_100533 | CO5 / IMSM_100882 | TripleTOF 5600+ System | ABI Sciex 5500 QTrap | high-resolution MS and tandem mass spectrometry (MS/MS) | Duo Spray Ion Source | Positive and Negative ran separately | SCIEX MarkerView Software |
| # | First Name | Last Name | Organization | Designation | |
|---|---|---|---|---|---|
| 1 | Joveeta | Joseph | joveeta@lvpei.org | LV Prasad Eye Institute | principal_investigator |
| 2 | Vivek | Pravin Dave | vivekdave@lvpei.org | LV Prasad Eye Institute | others |
| 3 | Dhanwini | Rudraprasad | dhanwini123@gmail.com | LV Prasad Eye Institute | research_scholar |
| 4 | Lakshminarayanan | Gowtham | gowthamkpm@gmail.com | LV Prasad Eye Institute | postdoctoral_researcher |
| 5 | Sreyasi | Maiti | sreyasideeni@gmail.com | LV Prasad Eye Institute | research_scholar |
| # | FTP Run ID | MS Exp ID | MS Data File |
|---|---|---|---|
| 1 | IMR_101105 | IME_100506 | A vs B Neg Individual Polarity (Raw).xlsx |
| 2 | IMR_101106 | IME_100507 | A vs B Pos Individual Polarity (Raw).xlsx |
| 3 | IMR_101107 | IME_100508 | A vs B Neg Individual Polarity (Raw).xlsx |
| 4 | IMR_101108 | IME_100509 | A vs B Pos Individual Polarity (Raw).xlsx |
| 5 | IMR_101109 | IME_100510 | A vs C Pos Individual Polarity (RAW).xlsx |
| 6 | IMR_101110 | IME_100511 | A vs C Pos Individual Polarity (RAW).xlsx |
| 7 | IMR_101111 | IME_100512 | A vs C Neg Individual Polarity (RAW).xlsx |
| 8 | IMR_101112 | IME_100513 | A vs C Pos Individual Polarity (RAW).xlsx |
| 9 | IMR_101113 | IME_100514 | C vs D Neg Individual Polarity (Raw).xlsx |
| 10 | IMR_101114 | IME_100515 | C vs D Pos Individual Polarity (Raw).xlsx |
| 11 | IMR_101115 | IME_100516 | C vs D Neg Individual Polarity (Raw).xlsx |
| 12 | IMR_101116 | IME_100517 | C vs D Pos Individual Polarity (Raw).xlsx |
| 13 | IMR_101117 | IME_100518 | C vs E Neg individual polarity (Raw).xlsx |
| 14 | IMR_101118 | IME_100519 | C vs E Pos Individual Polarity (Raw).xlsx |
| 15 | IMR_101119 | IME_100520 | C vs E Neg individual polarity (Raw).xlsx |
| 16 | IMR_101120 | IME_100521 | C vs E Pos Individual Polarity (Raw).xlsx |
| 17 | IMR_101121 | IME_100522 | E vs A Neg Individual Polarity (Raw).xlsx |
| 18 | IMR_101122 | IME_100523 | E vs A Pos Individual Polarity (Raw).xlsx |
| 19 | IMR_101123 | IME_100524 | E vs A Neg Individual Polarity (Raw).xlsx |
| 20 | IMR_101124 | IME_100525 | E vs A Pos Individual Polarity (Raw).xlsx |
| 21 | IMR_101125 | IME_100526 | E vs F Neg Individual Polarity (Raw).xlsx |
| 22 | IMR_101126 | IME_100527 | E vs F Pos Individual Polarity (Raw).xlsx |
| 23 | IMR_101127 | IME_100528 | E vs F Neg Individual Polarity (Raw).xlsx |
| 24 | IMR_101128 | IME_100529 | E vs F Pos Individual Polarity (Raw).xlsx |
| 25 | IMR_101129 | IME_100530 | A vs B Neg Individual Polarity (Raw).xlsx |
| 26 | IMR_101130 | IME_100531 | A vs B Neg Individual Polarity (Raw).xlsx |
| 27 | IMR_101131 | IME_100532 | A vs B Neg Individual Polarity (Raw).xlsx |
| 28 | IMR_101132 | IME_100533 | A vs B Neg Individual Polarity (Raw).xlsx |